Novo's Semaglutide Outperforms Lilly's Trulicity In SUSTAIN 7
Lilly's performance-based plans for Trulicity may be harder to sustain if Novo's competing once-weekly GLP-1 agonist semaglutide is approved in December, following superiority in a head-to-head diabetes study.
You may also be interested in...
Novo Nordisk Touts First-Line Potential For Oral Semaglutide
Novo's oral GLP-1 receptor agonist has a lot going for it in diabetes based on the latest data, but still needs to prove cardiovascular benefit; a new large outcomes study is now in the works.
ADA Meeting's Around The Corner: Five Things To Watch For
Among other debates at the American Diabetes Association annual meeting, clinicians will discuss the future of cardiovascular outcomes studies for diabetes drugs – whether they should maintain course or are due for an overhaul.
Novo Nordisk Plans Value-based Contracts For GLP-1 Agonist Ozempic
Company aims to shift gradually away from once-daily GLP-1 Victoza (liraglutide) toward once-weekly Ozempic (semaglutide).